This is a double-blind placebo controlled dose escalation trial evaluating efficacy and safety of inactivated rFVIIa (FFR-rFVIIa) as an antithrombotic agent. The trial showed a dose dependent prolongation of the prothrombin time. Future studies in patients undergoing vascular intervention are required. – M. Aldouri. FFR-rFVIIa is a variant activated factor VII molecule that is characterised […]
NATA: Network for the advancement of Patient Blood Manegement, Haemostasis and Thrombosis
MISSION: Providing a multidisciplinary forum for dialogue between haematologists, transfusion medicine specialists, anaesthesiologists, intensive care and emergency physicians, surgeons, perfusionists, nurses, biomedical scientists and ther heathcare professionals.
I am text block. Click edit button to change this text. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.